Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.26
NAS:SCMP's Cash-to-Debt is ranked lower than
81% of the 860 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. NAS:SCMP: 0.26 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:SCMP' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.26  Med: 3.6 Max: No Debt
Current: 0.26
0.26
No Debt
Equity-to-Asset 0.10
NAS:SCMP's Equity-to-Asset is ranked lower than
96% of the 789 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. NAS:SCMP: 0.10 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:SCMP' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.21  Med: 0.45 Max: 0.82
Current: 0.1
-0.21
0.82
Debt-to-Equity 7.41
NAS:SCMP's Debt-to-Equity is ranked lower than
99% of the 577 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.31 vs. NAS:SCMP: 7.41 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:SCMP' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.33  Med: 1.43 Max: 11.06
Current: 7.41
-0.33
11.06
Debt-to-EBITDA -2.88
NAS:SCMP's Debt-to-EBITDA is ranked lower than
99.99% of the 511 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. NAS:SCMP: -2.88 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NAS:SCMP' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -28.04  Med: 3.47 Max: 4.48
Current: -2.88
-28.04
4.48
Piotroski F-Score: 4
Altman Z-Score: 0.95
Beneish M-Score: -4.09
WACC vs ROIC
7.01%
-34.94%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % -44.03
NAS:SCMP's Operating Margin % is ranked lower than
83% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.71 vs. NAS:SCMP: -44.03 )
Ranked among companies with meaningful Operating Margin % only.
NAS:SCMP' s Operating Margin % Range Over the Past 10 Years
Min: -44.03  Med: 17.01 Max: 29.02
Current: -44.03
-44.03
29.02
Net Margin % -60.24
NAS:SCMP's Net Margin % is ranked lower than
83% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.73 vs. NAS:SCMP: -60.24 )
Ranked among companies with meaningful Net Margin % only.
NAS:SCMP' s Net Margin % Range Over the Past 10 Years
Min: -60.24  Med: 7.94 Max: 22.25
Current: -60.24
-60.24
22.25
ROE % -136.63
NAS:SCMP's ROE % is ranked lower than
94% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.80 vs. NAS:SCMP: -136.63 )
Ranked among companies with meaningful ROE % only.
NAS:SCMP' s ROE % Range Over the Past 10 Years
Min: -136.63  Med: 14.17 Max: 39.55
Current: -136.63
-136.63
39.55
ROA % -33.34
NAS:SCMP's ROA % is ranked lower than
84% of the 867 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.25 vs. NAS:SCMP: -33.34 )
Ranked among companies with meaningful ROA % only.
NAS:SCMP' s ROA % Range Over the Past 10 Years
Min: -33.34  Med: 4.54 Max: 19.13
Current: -33.34
-33.34
19.13
ROC (Joel Greenblatt) % -193.73
NAS:SCMP's ROC (Joel Greenblatt) % is ranked lower than
84% of the 850 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.46 vs. NAS:SCMP: -193.73 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:SCMP' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -193.73  Med: 82.98 Max: 529.23
Current: -193.73
-193.73
529.23
3-Year Revenue Growth Rate 35.70
NAS:SCMP's 3-Year Revenue Growth Rate is ranked higher than
93% of the 675 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. NAS:SCMP: 35.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:SCMP' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -21.2  Med: 22.7 Max: 128.6
Current: 35.7
-21.2
128.6
3-Year EBITDA Growth Rate 78.50
NAS:SCMP's 3-Year EBITDA Growth Rate is ranked higher than
94% of the 677 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. NAS:SCMP: 78.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:SCMP' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -19.8  Med: 67.8 Max: 206.8
Current: 78.5
-19.8
206.8
3-Year EPS without NRI Growth Rate 37.90
NAS:SCMP's 3-Year EPS without NRI Growth Rate is ranked higher than
83% of the 650 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.40 vs. NAS:SCMP: 37.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:SCMP' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -56.3  Med: 2.9 Max: 82.5
Current: 37.9
-56.3
82.5
GuruFocus has detected 6 Warning Signs with Sucampo Pharmaceuticals Inc NAS:SCMP.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:SCMP's 30-Y Financials

Financials (Next Earnings Date: 2018-03-08)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2017

SCMP Guru Trades in Q1 2017

Joel Greenblatt 219,916 sh (+296.19%)
Chuck Royce 974,023 sh (+24.55%)
Leon Cooperman Sold Out
Steven Cohen Sold Out
Paul Tudor Jones 67,771 sh (-0.06%)
Jim Simons 1,111,400 sh (-23.87%)
» More
Q2 2017

SCMP Guru Trades in Q2 2017

Chuck Royce 1,067,923 sh (+9.64%)
Jim Simons 810,600 sh (-27.06%)
Joel Greenblatt 85,967 sh (-60.91%)
Paul Tudor Jones 16,586 sh (-75.53%)
» More
Q3 2017

SCMP Guru Trades in Q3 2017

Steven Cohen 1,863,435 sh (New)
Jim Simons 1,305,700 sh (+61.08%)
Chuck Royce 1,171,731 sh (+9.72%)
Paul Tudor Jones Sold Out
Joel Greenblatt 39,830 sh (-53.67%)
» More
Q4 2017

SCMP Guru Trades in Q4 2017

Mario Gabelli 29,400 sh (New)
Pioneer Investments 22,000 sh (New)
John Paulson 1,600,000 sh (New)
Jim Simons 1,957,600 sh (+49.93%)
Joel Greenblatt Sold Out
Steven Cohen Sold Out
Chuck Royce 879,841 sh (-24.91%)
» More
» Details

Insider Trades

Latest Guru Trades with SCMP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2017-12-31 New Buy0.56%$9.5 - $18 $ 18.0046%1,600,000
Mario Gabelli 2017-12-31 New Buy$9.5 - $18 $ 18.0046%29,400
Joel Greenblatt 2017-12-31 Sold Out 0.01%$9.5 - $18 $ 18.0046%0
Joel Greenblatt 2017-09-30 Reduce -53.67%0.01%$10.05 - $13.1 $ 18.0061%39,830
Joel Greenblatt 2017-06-30 Reduce -60.91%0.02%$9.45 - $11 $ 18.0076%85,967
Joel Greenblatt 2017-03-31 Add 296.19%0.02%$10.25 - $13.95 $ 18.0055%219,916
Leon Cooperman 2017-03-31 Sold Out 0.03%$10.25 - $13.95 $ 18.0055%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:XKRX:000640, TSX:GUD, SHSE:600351, SZSE:002880, NYSE:LCI, NAS:FLXN, SZSE:300723, BOM:540222, NAS:EGRX, XKRX:001060, SZSE:002900, HKSE:02877, SZSE:300683, NAS:AMPH, TSE:4553, SZSE:000597, XKRX:170900, HKSE:01558, XCNQ:TRST, XBRU:FAGR » details
Traded in other countries:R3A.Germany,
Headquarter Location:USA
Sucampo Pharmaceuticals Inc is a pharmaceutical company having its primary market in the United States. It generates revenue from the sale of drugs for the treatment of gastrointestinal diseases.

Sucampo Pharmaceuticals Inc is a part of the healthcare sector in the United States. As a global pharmaceutical company, it commercializes drugs for the treatment of various gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It currently generates revenue mainly from product royalties, product sales, upfront and milestone payments, and reimbursements for development activities.

Top Ranked Articles about Sucampo Pharmaceuticals Inc

Boyd Gaming Set to Join S&P MidCap 400; Ring Energy, James River Group Holdings and EVERTEC to Join S&P SmallCap 600
Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Sucampo Pharmaceuticals, Inc. In The District Of Maryland
Lifshitz & Miller LLP Announces Investigation of Advanced Micro Devices, Aflac Incorporated, DST Systems, Inc., Forum Merger Corporation, GoPro, Inc., Sucampo Pharmaceuticals, Inc. and ZAIS Group Holdings, Inc.
Wolf Popper LLP Investigates the Proposed Acquisition of Sucampo Pharmaceuticals, Inc. by Mallinckrodt plc
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Sucampo Pharmaceuticals, Inc. -- SCMP
6 Stocks Move Higher After XMas Acquisition, approvals, ratings affected companies
Shares of Mallinckrodt Public Limited Co. (NYSE:MNK) traded more than 3% higher on news that the company will pay $18 per share in cash for Sucampo (NASDAQ:SCMP) on a deal valued at $1.2 billion. After the acquisition, Mallinckrodt expects EPS accretion of a minimum of $30 cents for next year, and more than $60 cents in 2019. Sucampo´s stock jumped about 6% after the $840 million (£628.8 million) news. Sucampo is working on drugs to combat two rare genetic diseases, with a potential high price if successful. Read more...
Mallinckrodt To Acquire Sucampo Pharmaceuticals For Approximately $1.2 Billion
Sucampo Pharmaceuticals Announces its Participation at the Global Mizuho Investor Conference
Sucampo Pharmaceuticals Announces its Participation at the Global Mizuho Investor Conference
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 29th Annual Piper Jaffray Healthcare Conference

Ratios

vs
industry
vs
history
Forward PE Ratio 11.99
SCMP's Forward PE Ratio is ranked higher than
70% of the 73 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.67 vs. SCMP: 11.99 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 21.15
SCMP's PB Ratio is ranked lower than
95% of the 825 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.79 vs. SCMP: 21.15 )
Ranked among companies with meaningful PB Ratio only.
SCMP' s PB Ratio Range Over the Past 10 Years
Min: 0.97  Med: 4.79 Max: 21.21
Current: 21.15
0.97
21.21
PS Ratio 3.78
SCMP's PS Ratio is ranked lower than
58% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. SCMP: 3.78 )
Ranked among companies with meaningful PS Ratio only.
SCMP' s PS Ratio Range Over the Past 10 Years
Min: 1.2  Med: 3.04 Max: 9.7
Current: 3.78
1.2
9.7
Price-to-Free-Cash-Flow 47.49
SCMP's Price-to-Free-Cash-Flow is ranked lower than
73% of the 217 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.63 vs. SCMP: 47.49 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
SCMP' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 3.67  Med: 27.96 Max: 326.79
Current: 47.49
3.67
326.79
Price-to-Operating-Cash-Flow 46.75
SCMP's Price-to-Operating-Cash-Flow is ranked lower than
84% of the 294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 18.74 vs. SCMP: 46.75 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
SCMP' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.62  Med: 27.53 Max: 160.85
Current: 46.75
3.62
160.85
EV-to-EBIT -8.07
SCMP's EV-to-EBIT is ranked lower than
99.99% of the 586 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.21 vs. SCMP: -8.07 )
Ranked among companies with meaningful EV-to-EBIT only.
SCMP' s EV-to-EBIT Range Over the Past 10 Years
Min: -2724.9  Med: 11.1 Max: 51.3
Current: -8.07
-2724.9
51.3
EV-to-EBITDA -10.46
SCMP's EV-to-EBITDA is ranked lower than
99.99% of the 612 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.57 vs. SCMP: -10.46 )
Ranked among companies with meaningful EV-to-EBITDA only.
SCMP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -746  Med: 8 Max: 193.6
Current: -10.46
-746
193.6
EV-to-Revenue 4.26
SCMP's EV-to-Revenue is ranked lower than
60% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. SCMP: 4.26 )
Ranked among companies with meaningful EV-to-Revenue only.
SCMP' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.1  Med: 3 Max: 9.1
Current: 4.26
0.1
9.1
Current Ratio 5.11
SCMP's Current Ratio is ranked higher than
77% of the 811 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.46 vs. SCMP: 5.11 )
Ranked among companies with meaningful Current Ratio only.
SCMP' s Current Ratio Range Over the Past 10 Years
Min: 1.27  Med: 3.75 Max: 9.5
Current: 5.11
1.27
9.5
Quick Ratio 4.46
SCMP's Quick Ratio is ranked higher than
78% of the 812 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.88 vs. SCMP: 4.46 )
Ranked among companies with meaningful Quick Ratio only.
SCMP' s Quick Ratio Range Over the Past 10 Years
Min: 1.27  Med: 3.75 Max: 9.21
Current: 4.46
1.27
9.21
Days Inventory 126.45
SCMP's Days Inventory is ranked lower than
55% of the 752 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.37 vs. SCMP: 126.45 )
Ranked among companies with meaningful Days Inventory only.
SCMP' s Days Inventory Range Over the Past 10 Years
Min: 2.34  Med: 69.48 Max: 164.56
Current: 126.45
2.34
164.56
Days Sales Outstanding 48.23
SCMP's Days Sales Outstanding is ranked higher than
74% of the 692 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.67 vs. SCMP: 48.23 )
Ranked among companies with meaningful Days Sales Outstanding only.
SCMP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.75  Med: 19.46 Max: 68.22
Current: 48.23
1.75
68.22
Days Payable 33.48
SCMP's Days Payable is ranked lower than
84% of the 630 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.56 vs. SCMP: 33.48 )
Ranked among companies with meaningful Days Payable only.
SCMP' s Days Payable Range Over the Past 10 Years
Min: 9.38  Med: 92.95 Max: 662.06
Current: 33.48
9.38
662.06

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.30
SCMP's 3-Year Average Share Buyback Ratio is ranked higher than
64% of the 534 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -5.00 vs. SCMP: -2.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SCMP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -9.6  Med: -0.65 Max: 0
Current: -2.3
-9.6
0

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 4.09
SCMP's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
64% of the 314 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.62 vs. SCMP: 4.09 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
SCMP' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.1  Med: 3.12 Max: 230
Current: 4.09
0.1
230
Price-to-Median-PS-Value 1.24
SCMP's Price-to-Median-PS-Value is ranked lower than
62% of the 694 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.05 vs. SCMP: 1.24 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SCMP' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.67  Med: 0.98 Max: 2.44
Current: 1.24
0.67
2.44
Earnings Yield (Greenblatt) % -12.39
SCMP's Earnings Yield (Greenblatt) % is ranked lower than
87% of the 868 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.18 vs. SCMP: -12.39 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SCMP' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -28  Med: 4.9 Max: 125.2
Current: -12.39
-28
125.2

More Statistics

Revenue (TTM) (Mil) $250.47
EPS (TTM) $ -3.28
Beta0.58
Short Percentage of Float24.13%
52-Week Range $9.30 - 18.75
Shares Outstanding (Mil)47.17

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 253 264 307 374
EBIT (Mil $) 115 109 147
EBITDA (Mil $) 115 109 148
EPS ($) 1.20 1.50 1.88 2.76
EPS without NRI ($) 1.20 1.50 1.88 2.76
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}